For decades, HIV has resisted a complete scientific answer — not for lack of effort, but because the virus mutates, hides, and endures. Now a small Hong Kong-backed biotech called Viva-Thera, working with XtalPi's artificial intelligence platform, has nominated a preclinical drug candidate in seven months by targeting a part of the virus that barely changes across strains, suggesting that the combination of deep structural biology and machine-scale computation may be quietly rewriting what is possible in the long human struggle against this disease.